By Matthew Stenger In a Canadian population-based study reported in the Journal of Clinical Oncology, Gupta et al found that survivors of childhood, adolescent, and young adult cancers were not at a greater risk of COVID-19 infection or severe complications of...
Immunogenicity of COVID-19 BNT162b2 mRNA Vaccine Booster in Patients With Cancer Receiving Active Treatment
By Matthew Stenger In an Israeli single-institution study reported in The Lancet Oncology, Ligumsky et al found that a booster dose of the SARS–CoV-2 Pfizer-BioNTech BNT162b2 mRNA vaccine given in August or September 2021 was immunogenic in patients receiving...
Fully Vaccinated Patients With Multiple Myeloma: Rates of SARS–CoV-2 Breakthrough Infection and Hospitalization
By Matthew Stenger In a U.S. cohort study reported in JAMA Network Open, Wang et al found that fully vaccinated patients with multiple myeloma were at increased risk of breakthrough SARS–CoV-2 infection, and that those with breakthrough infection were more likely...
Response to Third Dose of SARS–CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment
By Matthew Stenger In a single-institution Israeli study reported in a research letter in JAMA Oncology, Rottenberg et al found that a booster dose of the SARS–CoV-2 BNT162b2 mRNA resulted in increased spike protein antibody titers in patients with solid tumors...
All-Cause Mortality in COVID-19–Positive and COVID-19–Negative Patients With Cancer
6/18/2021 ~ The ASCO Post ~ By Matthew Stenger All-Cause Mortality in COVID-19–Positive and COVID-19–Negative Patients With Cancer In a large cohort study reported by Sharafeldin et al in the Journal of Clinical Oncology, researchers from the National COVID Cohort...